A golden opportunity
$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue or earnings
4. 150 million dollars shares repurchase program which accounts for approx. 30% of their current shares outstanding
5. company had diversified its portfolio with 3 drugs in the pipeline.
Bad news:
1. eVenus generic version of Experal harms its top and bottom line, but it has to overcome all the patent dispute above.
Clearly the market has priced in the decline or even bankrupt of the PCRX twice recently (-20% and -48%), but the company may survives or even thrive just fine. It’s a huge buy opportunity if you think PCRX will survive.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Graduate with Economic and Math degree. Been tracking and learning in the market for over 7 years. Student of Buffett.
4Followers
5Following
18Visitors
Follow
Value investorr OP : Whoever saw this post and bought around this time has probably made really really good returns, shout out to all my fellow shareholders $iShares Russell 2000 ETF (IWM.US)$.